About us - patients - St Pancras Clinical Research

St Pancras Clinical Research

A New and Innovative

Site Management Organisation

St Pancras Clinical Research (SPR) is a London-based Site Management Organisation which conducts clinical trials with new medicines for patients with neurodegenerative conditions resulting in chronic pain and/or memory disorders.

Our clinical and scientific specialists offer wide-ranging and practical expert advice to Sponsors on their drug development programmes, based individually upon 30+ years of experience in the public, private, academic and commercial pharma fields.

This message is only visible to admins.
Problem displaying Facebook posts. Backup cache in use.
Click to show error

Error: Error validating access token: The session has been invalidated because the user changed their password or Facebook has changed the session for security reasons. Type: OAuthException

Target Audience

Medium Businesses
Freelance Designers
College Students
Sorta Athletes
Dairy Farmers

Our Specialties

Program Management
Graphic & UI Design
Customer Support
Video Editing
Sound Design

Notable Awards

Top Customer Support
Most Liked Company
Best In Class 2016
Friendliest Group
Innovative Brand

Featured On

ThemeNectar Show
Mr. Nectar’s Blog
Top WP Themes
ThemeForest
Salient

The best talent.

A world class environment.

Medicines that make a difference.

We (‘SPR’) will seek out the best ideas, science and talent and create a world class environment that stimulates creativity, encouraging innovation and collaboration to deliver medicines that make a difference to patients’ lives.

Central London clinic.

Unrivalled subject recruitment potential.

Connections to primary care and specialist centres.

SPR’s first research clinic is three minutes walk from London’s largest rail and Tube hub (King’s Cross St Pancras) and adjacent to two University College London Hospitals NHS Foundation Trust specialist hospitals. Our screening and out-patient clinic is very accessible to any study participant coming from London and surrounding areas.

With a catchment area of 8.5 million inhabitants in Greater London, and a further 8 million across the South East, SPR has unrivalled subject recruitment potential. In addition, connections to both primary care and specialist centres in London will facilitate enrolment of patient groups that are typically more difficult to identify, thereby reducing recruitment costs.

The St Pancras team

David James

CEO

29 years spent in international investment banking. Broad range of experience advising major corporations and boards.

Currently joint head of UK investment banking at UBS. Previously, Vice Chairman of EMEA Banking at Citigroup. David graduated from Cambridge University with a Masters degree.

Dr Stuart Ratcliffe

Chief Scientific Officer

27 years experience in clinical research phases I-IV. Conducted over 200 clinical trials as principal, Chief and Coordinating Investigator. Developed and led trial programmes in the public (NHS), academic (QMUL), pharmaceutical and private sectors.

Active participant in academic and pharmaceutical expert advisory boards. Clinical and regulatory expert in the fields of centrally and peripherally acting analgesics and cannabinoids.

Professor Richard Langford

Chief Medical Officer

25 years experience in clinical research phases I-IV in the fields of pain and anaesthesia. Founder Director of the Pain and Anaesthesia Research Centre at Barts NHS Health Trust, Professor at City University, London, Clinical Director of Anaesthetics, Critical Care and Pain Medicine.

Previously Clinical Director of the Joint Hospital and Medical School Clinical Research Centre; Chair of the Operations Board of the first Quintiles Global Prime Site at Barts and the London Medical School, President of the British Pain Society (2010-13), EFIC Council Member and Board member of the Faculty of Pain Medicine.

Professor Roger Bullock

Deputy Chief Medical Officer

30+ years experience in all clinical research phases in psychiatry and old age psychiatry. Founded and led the KingHill Research Centre, consistently high recruitment in AD & MCI studies.

KOL and senior therapeutic advisor for most CNS pharma companies.